Spotlight Medical develops AI-driven prognosis tests that analyze decades of patient treatment data to help physicians choose the most effective cancer therapies. The company uses advanced AI algorithms to reduce over- and under-treatment and improve patient outcomes. Founded in 2024 and backed by Institut Curie and Gustave Roussy, Spotlight is focused on commercializing its first prognosis test. The recently announced seed financing will enable the company to bring that initial test to the clinic. Spotlight emphasizes close collaboration with physicians to address unmet clinical needs and translate its models into actionable clinical tests. Investors highlighted the strength of the team and the distinctiveness of the company’s precision oncology technology.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2024